Eiger Biopharmaceuticals's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Eiger Biopharmaceuticals is scheduled to report earnings on March 14, 2024, and the estimated EPS forecast is €-6.34. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 3.21M	$ 4.39M	$ 4.12M	$ 2.70M	$ 4.02M
Gross Profit	$ 3.21M	$ 4.33M	$ 4.00M	$ 2.35M	$ 2.79M
EBIT	$ -16.62M	$ -19.35M	$ -21.50M	$ -24.39M	$ -26.02M
EBITDA	-	$ -19.21M	$ -21.32M	$ -23.82M	$ -25.81M
Net Income Common Stockholders	$ -18.03M	$ -20.70M	$ -22.78M	$ -25.14M	$ -27.11M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 39.42M	$ 53.63M	$ 75.29M	$ 98.95M	$ 121.04M
Total Assets	$ 55.65M	$ 72.38M	$ 98.44M	$ 120.14M	$ 143.74M
Total Debt	$ 40.94M	$ 40.67M	$ 40.42M	$ 40.20M	$ 39.59M
Net Debt	$ 1.52M	$ -12.96M	$ -34.87M	$ -58.75M	$ -81.45M
Total Liabilities	$ 57.26M	$ 57.06M	$ 63.99M	$ 64.83M	$ 65.44M
Stockholders Equity	$ -1.60M	$ 15.27M	$ 35.22M	$ 55.31M	$ 78.31M
Cash Flow	-
Free Cash Flow	-	$ -22.05M	$ -24.22M	$ -22.47M	$ -20.67M
Operating Cash Flow	$ -14.56M	$ -22.04M	$ -24.00M	$ -22.25M	$ -20.56M
Investing Cash Flow	$ 19.00M	$ 29.85M	$ 13.38M	$ 21.80M	$ 10.38M
Financing Cash Flow	$ 15.00K	$ -22.00K	$ 41.00K	$ -60.00K	$ -88.00K

Currency in USD

Eiger Biopharmaceuticals Earnings and Revenue History

Income Statement >

Eiger Biopharmaceuticals Debt to Assets

Balance Sheet >

Eiger Biopharmaceuticals Cash Flow

Cash Flow >

Eiger Biopharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing